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Abstract
Introduction: Randomized clinical trials have demonstrated the efficacy of antiretroviral pre-exposure prophylaxis (PrEP) in
preventing HIV acquisition among men who have sex with men (MSM). However, limited research has examined initiation and
adherence to PrEP among Black MSM (BMSM) in the United States (US) who are disproportionately represented among
newly HIV infected and late to care individuals. This research reports on the HIV Prevention Trials Network 073 (HPTN 073)
study aimed to examine PrEP initiation, utilization and adherence among Black MSM utilizing the theoretically principled, cul-
turally informed and client-centered care coordination (C4) model.
Methods: The HPTN 073 study enrolled and followed 226 HIV-uninfected Black MSM in three US cities (Los Angeles, CA;
Washington DC; and Chapel Hill, NC) from February 2013 through September 2015. Study participants were offered once
daily oral emtricitabine/tenofovir (FTC/TDF) PrEP combined with C4 and followed up for 52 weeks. Participants received HIV
testing, risk reduction education and clinical monitoring.
Results: Of the 226 men enrolled, 178 participants initiated PrEP (79%), and of these 64% demonstrated PrEP utilization at
week 26 (mid-point of the study) based on pharmacokinetic testing. Condomless anal sex with an HIV-infected or unknown
status casual male partner was statistically significantly associated with a greater likelihood of PrEP initiation (adjusted odds
ratio (OR) 4.4, 95% confidence interval (CI) 1.7, 11.7). Greater age (≥25 vs. <25, OR 2.95, 95% CI 1.37 –6.37), perception of
having enough money (OR 3.6, 95% CI 1.7 to 7.7) and knowledge of male partner taking PrEP before sex (OR 2.22, 95% CI
1.03 to 4.79) were statistically significantly associated with increased likelihood of PrEP adherence at week 26. Annualized
HIV incidence was 2.9 (95% CI 1.2 to 7.9) among those who initiated PrEP, compared to 7.7 (95% CI 2.5 to 24.1) among
those who did not initiate PrEP (p = 0.18).
Conclusions: Results suggest a high level of PrEP initiation among at-risk Black MSM, a group historically characterized as
hard to reach. The data support the importance of addressing contextual factors that affect PrEP initiation and adherence, and
of additional research on the ultimate benefit of PrEP in HIV prevention among Black MSM.
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1 | INTRODUCTION
In 2016, Black men who have sex with men (BMSM) consti-
tuted the highest proportion (38%) of new HIV infections
diagnosed in the US as compared to Latino (28%) and White
(28%) MSM [1–5]. Based on current rates of HIV diagnoses
epidemiological data suggest Black US MSM have a 50%
probability of acquiring HIV in their lifetime with young Black
men (under 25) being at significant risk within this population
[6]. Identifying effective interventions to reduce HIV burden
among Black MSM is a priority in the US National HIV Strat-
egy [7].
A constellation of factors contribute to increased HIV infec-
tions among Black MSM, including higher levels of unrecog-
nized HIV and sexually transmitted infections (STI), and
delayed initiation of antiretroviral therapy [3,5,8–12]. Struc-
tural factors, such as lower income, un-/under-employment,
educational inequalities, inadequate access to healthcare and
treatment, incarceration, stigma and discrimination also influ-
ence the incidence and prevalence of HIV among Black MSM
Wheeler DP et al. Journal of the International AIDS Society 2019, 22:e25223
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25223/full | https://doi.org/10.1002/jia2.25223
1
[13–19]. Research also documents inadequate incorporation of
Black researchers in conducting HIV prevention and clinical
studies focused on Black communities. This lack of representa-
tion may influence the design and interpretation of studies
[20].
Along with behavioural interventions [21–26], early HIV
diagnosis and linkage to care and treatment [27–29], use of
antiretroviral drugs as pre-exposure prophylaxis (PrEP) is criti-
cal for the prevention of HIV acquisition [30–36]. Clinical
studies have demonstrated the efficacy of oral daily PrEP
along with counselling in preventing HIV acquisition in MSM
[31,32,37]. Mathematical modelling indicates that approxi-
mately 20% to 25% of new HIV infections among MSM glob-
ally could be reduced with expanded access to PrEP [38,39].
Limited research is available on the initiation of and adher-
ence to PrEP among Black MSM in the US [40–45]. The
importance of developing effective interventions and methods
for delivering these interventions is essential to reducing the
disproportionate HIV burden among BMSM in the United
States inclusive of health provider biases [21,30,40].
Evidence-based research is needed to address this vital
public health priority, including culturally sensitive care and
support services that address the structural barriers [40–45].
We report results from an open-label antiretroviral PrEP
demonstration project, HIV Prevention Trials Network 073
(HPTN 073) that examined the uptake/initiation and adher-
ence with daily oral co-formulated emtricitabine and tenofovir
disoproxil fumarate (FTC/TDF) among Black MSM in three US
cities.
A theoretically principled and culturally informed interven-
tion, client-centred care coordination (C4), was developed for
use in this study to support participants’ PrEP understanding,
initiation and adherence [34–37].
2 | METHODS
2.1 | Ethics statement
The HPTN 073 Study protocol and all related materials were
reviewed and approved by institutional review boards of
University of California at Los Angeles, The University of
North Carolina at Chapel Hill and George Washington Univer-
sity. All study participants provided written informed consent
and completed an informed consent assessment to ensure a
thorough understanding of the study prior to enrolment.
Ongoing informed consent was assessed and confirmed at
each visit.
2.2 | Study design and participants
This non-randomized open-label PrEP study was conducted
among MSM who self-identified as Black in three US cities.
Enrolment eligibility criteria included: (1) being 18 years and
older; (2) serologically confirmed HIV-uninfected; (3) biologi-
cally male at birth; (4) self-report at least one of the following:
condomless receptive or insertive anal intercourse with a male
partner, having any anal intercourse with more than three
male sex partners; having exchanged any anal sex with a male
partner for money gifts, shelter or drugs; having any anal
intercourse with a male partner while using drugs or alcohol;
diagnosed with an STI and having a male sex partner in the
past six months; (5) willingness to provide locator information
for study follow-up; and (6) meeting clinical safety criteria
related to PrEP eligibility including urine dipstick negative or
trace for protein and glucose, haemoglobin >11 g/dL, and
being HBV-uninfected. Potential participants were excluded if
they reported using antiretroviral drugs in the 60 days
prior to enrolment or if they were unable to provide informed
consent.
2.3 | Recruitment and follow-up
Recruitment of Black MSM participants occurred between
February 2013 and September 2014. Study sites were Wash-
ington, The District of Columbia; Los Angeles, California; and
Chapel Hill, North Carolina. Each site participated in commu-
nity outreach and cultural competency training developed and
facilitated by the HPTN Black Caucus [46] to ensure consis-
tency in outreach, recruitment and implementation efforts
while respecting site-specific approaches to local recruitment
methods. Recruitment strategies included peer referral, venue-
based sampling, local media and word-of-mouth often con-
veyed by local health providers or others engaged with PrEP
and/or Black MSM communities. Study participants were
followed up for a 52-week period.
2.4 | Interviewer administered questions
Trained interviewers collected sociodemographic (e.g. age, sex-
ual identity) participant data [5,20]. Perception of insufficient
income was assessed by asking participants whether they had
enough money for household expenses, such as rent, food
and/or utilities in the six months prior to assessment and was
coded as a dichotomous variable: (1) Yes=once in a while,
fairly often or very often and (2) No=never.
2.5 | ACASI administered questions
Participants completed an audio-computer assisted self-inter-
view (ACASI) at enrolment and study visits at weeks 4, 8,
13, 26, 39 and 52, including items described below. Sexual
behaviour items adapted from previous research [22] with
Black MSM included primary male partners (defined as
“someone who you would describe as your boyfriend, lover,
life partner, or someone you may have lived with or saw a
lot, or to whom you felt a special emotional commitment”),
casual male partners (defined as someone who you had sex
with casually or would describe as a one-night stand, sex
buddy, anonymous sex partner, or another male sex partner
who was not your primary or main partner), cisgender
female partners, and exchange sex partners, and insertive
and receptive anal intercourse acts with primary and casual
male partners during the three months prior to assessment.
Anal intercourse items (insertive and receptive) were strati-
fied by the HIV serostatus of male sexual partners (HIV-
infected, HIV non-infected and HIV status unknown). Items
related to female cisgender sex partners included vaginal
and anal sex (with and without condoms) during the three
months prior to assessment.
Substance use items asked about the self-reported fre-
quency of (never; once; one to two days a month; three to
four days a month; one to two days a week; three to four
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days a week; daily) alcohol and drug use within the three
months prior to assessment. Substances assessed included
alcohol, marijuana, cocaine (crack and powder), metham-
phetamine, heroin, non-prescribed painkillers or anti-anxiety
medications, non-prescribed erectile promotion drugs, inhaled
nitrates (poppers), anabolic steroids and female sex hormones.
Based on prior studies of substance use with Black MSM
[47–50], a binary variable (Yes/No) was created to measure
substance use.
Depressive symptoms
A brief version of the Center for Epidemiologic Depression
(CESD) Scale (CESD-10) was used to assess depressive symp-
toms [51,52] (alpha reliability coefficient = 0.89). A sum of the
scores was computed using a cutoff score of ≥10 to catego-
rize participants as being positive for depressive symptoms.
Incarceration
Based on research with Black MSM [18] incarceration was
defined as having ever spent one or more nights in a jail,
detention facility or prison.
PrEP-related knowledge
Two items measured aspects of PrEP knowledge: (1) knowl-
edge that an HIV-negative partner was taking PrEP before
having sex and (2) knowledge that PrEP could be used to pre-
vent HIV infection [5].
2.6 | Testing
All participants were asked to provide specimens for HIV, STI
and measuring PrEP drug levels at study visits. HIV testing
was performed at each study visit using US Food and Drug
Administration (FDA)-approved assays, including at least one
HIV rapid test and at least one-fourth-generation HIV test.
Serologic tests for syphilis were performed using local site-
specific testing algorithms. Testing for Chlamydia trachomatis
(CT) and Neisseria gonorrhoeae (NG) were performed for urine
and rectal swab samples using the Aptima Combo 2 Assay for
CT/NG assay at the local laboratories.
For all participants, creatinine clearance was measured at
the screening visit, and at the 4 and 13-week postenrolment
visits and quarterly thereafter if the participant-initiated PrEP
[53,54]. Urine dipstick for protein and glucose was also per-
formed at screening and quarterly after enrolment. Partici-
pants with laboratory abnormalities had their findings and
clinical care on protocol managed by study clinicians. When
indicated, participants were referred to primary care physi-
cians in the community for ongoing or non-study-related clini-
cal assistance.
2.7 | Client-centred care coordination (C4)
intervention and PrEP
The C4 intervention integrates an evidenced-based public
health strategy comprehensive risk counselling and services
(CRCS) with a self-determination theory (SDT)-based
approach to counselling and client engagement [55,56]. The
CRCS combines HIV risk reduction counselling with case
management activities to address potential barriers to HIV
prevention goal attainment [57]. Both provided conceptual
and explanatory bases for C4 activities including behavioural
counselling, care coordination, referrals and follow-up care.
The use of SDT as a foundation for the C4 intervention to
facilitate PrEP initiation and adherence was supported by
prior research indicating that SDT was associated with
increased recent HIV prevention behaviours (condom use for
anal sex) among MSM [58] and antiretroviral medication
adherence [56]. Moreover, the use of this theoretical founda-
tion was supported by a well-established research literature
on the efficacy of SDT-based approaches in promoting beha-
vioural risk-reduction and treatment adherence in other
health domains [59–62]. Critical to C4 success was the train-
ing and ability of counsellors in assisting participants to
address complex health and social realities of BMSM (pre-
sent and historical) and demonstrating connection and caring
for the life beyond adherence to a medication regimen [55].
2.8 | C4 encounters
All participants received an initial C4 session in which they
identified HIV prevention goals in the context of possible
PrEP initiation and adherence. C4 counselling was offered at
each study visit, and participants could decline the counselling
if not desired. Case report forms documented C4 sessions,
and the number of encounters was calculated as a continuous
variable.
2.9 | PrEP
Participants were offered and could initiate their study PrEP
regimen at any time between enrolment and week 48 of the
study period. Men seeking to initiate PrEP after this period
were referred to community providers. Participants were
under no obligation to initiate PrEP and could start and stop
taking it at any time during the study. The C4 model included
transitioning to community-based clinical management of PrEP
after participants exited the study at week 52.
No C4 follow-up support was provided after participants
exited the study.
2.10 | HIV testing
The HPTN Laboratory Center (LC) performed Quality Assur-
ance testing using the Abbott Architect HIV 1/2 Combo test.
Incident HIV infections were confirmed at the HPTN LC using
a panel of assays that included the Bio-Rad GS Combo Ag/Ab
EIA test and the Bio-Rad MultiSpot HIV-1/HIV-2 Rapid test.
Qualitative HIV RNA testing was performed using the
APTIMA HIV-1 RNA Qualitative Assay to determine if the
participant had acute HIV infection at the visit prior to HIV
seroconversion. Viral load and CD4 cell count testing were
performed at study sites for participants who acquired HIV
infection during the study.
2.11 | Safety monitoring
Assessment for adverse events (AEs) was performed at follow-
up visits for all study participants, regardless of whether they
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were or were not on PrEP. Clinically diagnosed STIs and all
conditions that resulted in a clinical hold or permanent discon-
tinuation of the study PrEP regimen were reported as AEs.
Conditions that caused the study PrEP to be held or perma-
nently discontinued included regimen-related toxicity or abnor-
mal laboratory values; investigator decision; a reactive HIV test
or concern about acute HIV infection; participant decision to
stop study drug or request “drug holiday”; missed visits; or par-
ticipant hospitalization. AEs were graded using the NIH DAIDS
AE Grading Table, Version 1.0, December 2004 [62].
2.12 | Study outcomes: PrEP initiation and
adherence
The main outcomes for this non-randomized acceptability and
feasibility study were PrEP initiation and adherence, measured
as the percentage of men who initiated study PrEP at any point
from enrolment to week 48 of the follow-up period. PrEP initia-
tion was defined as the date the participant took the first dose,
by self-report, and adherence was determined by pharmacolog-
ical testing of two types of participant specimens: plasma and
peripheral blood mononuclear cells (PBMCs) collected at week
26 (midpoint of the study) [32]. PrEP adherence was defined as
those who met the 90% sensitivity threshold for ≥4 doses of
FTC/TDF per week from any of the two samples types (Plasma
and PBMC) related to tenofovir (TFV) and FTC measurements:
≥4.2 ng/mL for TFV and ≥4.6 ng/mL for FTC in plasma;
9.9 fmol/106 for TFV diphosphate and 0.4 fmol/106 for FTC
triphosphate in PBMCs. These measures of adherence for
plasma and PBMC samples were established by the directly
observed daily dosing study, HPTN 066 [63].
2.13 | Statistical methods
Baseline characteristics, socio-demographics, sexual behaviour,
incarceration, substance use and C4 encounters were summa-
rized using measures of central tendency. PrEP initiation, and
adherence were estimated using proportions. Correlates of
PrEP initiation and PrEP adherence at the week 26 study visit
for those who had initiated PrEP were examined separately
using univariate and multivariate adjusted logistic regression
models. Correlates that were identified in univariate logistic
regression models with p < 0.05 were further selected for
inclusion in backward stepwise multivariate logistic regression
models. The cutoff of p < 0.05 in the multivariate logistic
regression models was considered statistically significant. In all
models, study site was included as a covariate to account for
heterogeneity among the sites. HIV incidence rates were cal-
culated using person-year analysis. For those who serocon-
verted, person-year is calculated from the enrolment date to
first HIV-positive test result date, and for those who remained
HIV negative, the person year is calculated from enrolment
date to the last test result date. All statistical analyses were
performed using SAS version 9.4.
3 | RESULTS
3.1 | Study recruitment and retention
Of the 344 individuals screened, 226 eligible participants
enrolled (66%) in the study. Abnormal liver or kidney
laboratory tests were the most common reasons for ineligibil-
ity (Figure 1). Study retention was 92% of enrolled partici-
pants completing the week 52 follow-up visit.
3.2 | Participant characteristics
Of the 226 participants enrolled, 86% self-identified as Black
or African American only, while the remaining included Afro-
Caribbean, African and Afro-Latino. Median age was 26
(IQR: 23 to 32) with 40% being 25 years old or younger.
One-quarter (25%) had a high school diploma or less; more
than one-third (38%) worked full-time, and 27% were unem-
ployed; 48% reported an annual income of less than
$20,000. More than half (69%) had health insurance. Nearly
three-quarters identified as gay (73%) and 20% identified as
bisexual. Most participants were single (83%). Of the 39 indi-
viduals who reported being in relationships, 36 (92%) had
male partners (Table 1).
3.3 | PrEP initiation and adherence
A total of 178 (79%) participants initiated PrEP during the
course of the study, 153 (68%) at enrolment and 25 (11%) at
a later visit (Figure 1). At the week 26 visit, based on 161
pharmacological measurements, 64% of participants who initi-
ated PrEP met the criteria for the 90% sensitivity threshold
for taking the pills ≥4 days per week in at least one of the
pharmacological measures and were defined as being adher-
ent to PrEP.
3.4 | Correlates of PrEP initiation
In univariate analyses, participant’s employment status (part-
time/self-employed odds ratio (OR) 2.30, 95% CI 1.02 to
5.20, and full-time OR 2.47, 95% CI 1.10 to 5.59 vs. being
unemployed), perception of having enough money (OR 2.12,
95% CI 1.08 to 4.16), use of drugs other than alcohol and
marijuana (OR 2.16, 95% CI 1.04 to 4.49), having any
casual male partners (OR 2.11, 95% CI 1.05 to 4.27), con-
domless anal sex with HIV-infected or unknown status
casual male partner (OR 4.40, 95% CI 1.66 to 11.69),
knowledge that an HIV-non-infected partner was taking
PrEP before having sex (OR 2.89, 95% CI 1.46 to 5.74)
and knowledge that PrEP could be used to prevent HIV
infection (OR 3.69, 95 CI 3.69 to 7.50) were significantly
associated with PrEP initiation.
In multivariate analyses, only condomless anal sex with an
HIV-infected or status unknown casual partner remained sta-
tistically significantly associated with PrEP initiation (AOR:
443, 95% CI: 1.68 to 11.68).
3.5 | Correlates of PrEP adherence
In univariate analysis, participants’ age (≥25 vs. <25, OR
4.03, 95% CI 1.96 to 8.28), two-year college or greater
(OR 6.80, 95% CI 2.54 to 18.2), full-time employment status
(OR 2.62, 95% CI 1.04 to 6.61), annual income of ≥40K
(OR 4.40, 95% CI 1.66 to 11.60), perception of having
enough money (OR 3.59, 95% CI 1.78 to 7.24), knowledge
of male partner taking PrEP before sex (OR 2.15, 95% CI
1.07 to 4.31), and knowledge of PrEP to prevent HIV
Wheeler DP et al. Journal of the International AIDS Society 2019, 22:e25223
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25223/full | https://doi.org/10.1002/jia2.25223
4
infection (OR 2.48, 95% CI 1.19 to 5.18), were significantly
associated with PrEP adherence at the week 26 visit
(Table 2).
In multivariate analysis, older age (≥25 vs. <25, OR 2.95,
95% CI 1.37 to 6.37), perception of having enough money
(OR 3.58, 95% CI 1.66 to 7.74), and knowledge of male part-
ner taking PrEP before sex (OR 2.22, 95% CI 1.03 to 4.79)
were associated with an increased odds of PrEP adherence at
the week 26 visit.
3.6 | Adverse events
Twenty-one serious adverse events (SAEs) were reported
during the study, with five among participants who had not
initiated PrEP. One of the 16 SAEs reported for PrEP initia-
tors was judged to be related to the PrEP regimen (i.e.
migraine equivalent syndrome). The most common SAEs
were psychiatric or nervous system disorders (n = 9) and
injuries (n = 4).
Reported abnormal laboratory values included 11 creatinine
elevations (one grade 2 (moderate) and 10 grade 1 (mild));
nine were in participants who initiated PrEP, with six events
judged to be related to the study PrEP regimen. All creatinine
elevations in participants who initiated PrEP had resolved
prior to their exit visit. Creatinine elevations did not result in
discontinuation of study medication. Two fractures were
reported for participants and were judged to be unrelated to
the study medication.
Among those who initiated PrEP, no increases were
reported over time in the number of male partners with med-
ian of 3 (IQR: 1 to 5) (Table 2).
3.7 | HIV incidence
Among the 178 men who initiated PrEP, five incident HIV
infections occurred in 172 person-years (PY) of follow-up (an-
nualized incidence = 2.9; 95% CI: 1.2 to 7.0) compared to
three infections in 39 PY of follow-up (annualized inci-
dence = 7.7; 95% CI: 2.5 to 24.1) among men who never initi-
ated PrEP; the difference between the two incidence rates
was non-significant (p = 0.1849). Of the five HIV seroconver-
sion among PrEP initiators, two had permanently discontinued
PrEP at 50 and 272 days prior to detection of HIV serocon-
version; two participants had no detectable TFV or FTC in
any samples; and one participant had a low level of FTC con-
sistent with ≤1 dose per week indicating that the participant
was not adherent to the daily regimen [64].
4 | DISCUSSION
HPTN 073, to the best of our knowledge, was the first
open-label study to specifically evaluate PrEP initiation, and
adherence among Black MSM in the US that utilized a theo-
retically principled, culturally informed intervention to sup-
port PrEP uptake and adherence. Findings from this
demonstration project suggest that recruitment, PrEP
uptake/initiations, adherence and retention of Black MSM
was feasible. Our findings on initiation and adherence to
PrEP are comparable to, or exceeded, those reported in
large-scale PrEP randomized controlled trials [32,34], but
included relatively small samples of Black MSM. Based on
limited safety and tolerability findings for this population, our
Enrolled
226 (66%)
Visit completion 
Week 4     173 (97%)
Week 8     166 (93%) 
Week 13   171 (96%)
Week 26   169 (95%)
Week 39   167 (94%)
Week 52    171 (96%)
Total never Initiated PrEP 
48 (21%)
Screened 344
Reasons not enrolled
34 Abnormal liver or kidney function or lab tests
18 Withdrew consent/unwilling
7 HIV+ rapid test
5 Unable to complete enrollment w/in 45 days
4 Current/prior study participation
4 Serious and active mental or medical illness
46 Other reasons
Visit completion 
Week 4    41 (85%)
Week 8    36 (75%) 
Week 13  37 (77%)
Week 26   36 (75%)
Week 39  36 (75%)
Week 52  38 (79%)
Total PrEP Initiators 
178* (79%)
*At enrollment 153, and follow-up 25
Figure 1. Study CONSORT diagram.
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Table 1. Baseline characteristics of Black men who have sex with men (MSM) enrolled in HIV prevention trials network study 073;
N = 226
GWUa
(N = 75)
UCLAa
(N = 76)
UNC AIDSa
(N = 75)
Totala
(N = 226)
PrEP initiatedb 80% (60) 67% (67) 89% (67) 79% (178)
Demographic characteristics
African Americanc 84% (63) 82% (62) 93% (70) 86% (195)
Age ≥25 years 55% (41) 70% (53) 55% (41) 60% (135)
Median (IQR) 28 (23 to 29) 32 (24 to 39) 28 (22 to 31) 26 (23 to 32)
Highest education level attained
HS or less 17% (13) 34% (26) 23% (17) 25% (56)
Some college or vocational school 40% (30) 36% (27) 48% (36) 41% (93)
Two-year college or greater 43% (32) 30% (23) 29% (22) 34% (77)
Employment status
Unemployed, disabled or other 20% (15) 38% (29) 23% (17) 27% (61)
Part time or self-employed 29% (22) 37% (28) 40% (30) 35% (80)
Full time 51% (38) 25% (19) 37% (28) 38% (85)
Annual income
No response 4% (3) 0% (0) 0% (0) 1% (3)
<$20K 23% (17) 66% (50) 55% (41) 48% (108)
$20K to $40K 21% (16) 21% (16) 31% (23) 25% (55)
≥$40K 52% (39) 13% (10) 15% (11) 27% (60)
Have enough money 65% (49) 45% (34) 68% (51) 59% (134)
Health insurance (current) 80% (60) 63% (48) 63% (47) 69% (155)
Gay 80% (60) 74% (56) 67% (50) 73% (166)
Bisexual 16% (12) 21% (16) 23% (17) 20% (45)
Married/significant other 25% (19) 13% (10) 13% (10) 17% (39)
Ever been incarcerated 26% (19) 49% (37) 18% (13) 31% (69)
Depressive symptomsd 25% (19) 33% (25) 29% (22) 29% (66)
Substance use in the last three months
Any alcohol use 89% (67) 83% (63) 92% (69) 88% (199)
Any marijuana use 53% (40) 57% (43) 36% (27) 49% (110)
Any other drug use 85% (64) 72% (55) 92% (69) 83% (188)
Any poly drug use 7% (5) 18% (14) 11% (8) 12% (27)
Sexual behaviours/characteristics
Age at first sexual encounter, median (Q1, Q3) 14 (10,16) 13 (8,15) 14 (12,17) 14 (10,16)
Any baseline sexually transmitted infection 16% (12) 9% (7) 17% (13) 14% (32)
Sexual behaviours in the last three months
Number of male partners, median (IQR) 2 (1,4) 3 (1,5) 3 (1,4) 3 (1,4)
Sex with a male partner 93% (70) 93% (71) 92% (69) 93% (210)
Had a primary male partner 35% (26) 38% (29) 25% (19) 33% (74)
Any condomless anal sex with HIV positive or
unknown primary male partner
13% (10) 9% (7) 9% (7) 11% (24)
Had a casual male sex partners 64% (48) 71% (54) 79% (59) 71% (161)
Any condomless anal sex with HIV positive
or unknown casual male partner
28% (21) 37% (28) 37% (28) 34% (77)
Had a female sex partner 8% (6) 13% (10) 15% (11) 12% (27)
Any condomless anal sex with female partner 7% (5) 11% (8) 4% (3) 7% (16)
Exchanged sex for money 11% (8) 16% (12) 9% (7) 12% (27)
GWU, George Washington University; IQR, interquartile range; UCLA, University of California at Los Angeles; UNC AIDS, University of North
Carolina Centre for AIDS Research. aRow totals may not add up to group totals due to missing data (not shown). bOverall, 153 initiated PrEP at
enrolment, and 25 during follow-up. cThe rest belong to African, Afro-Caribbean, Afro-Latino or other. dCESD10 score of 10+.
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results provide additional data [33,41] that support the
safety of daily oral PrEP among BMSM.
Our findings suggest BMSM are willing to initiate PrEP and
that this decision can be supported with interventions and
improved access to consistent healthcare [5–16,42].
This is particularly salient in that this population faces multi-
ple forms of structural inequalities and studies have shown
that these barriers often influence PrEP uptake and utilization
among Black MSM [41,65–67]. For example, in this study,
multivariate analyses show that condomless anal sex with an
Table 2. Correlates of PrEP initiation and adherence among Black men who have sex with men enrolled in HIV prevention trials
network study 073
PrEP initiation (N = 178a) PrEP adherence (N = 161a,b)
PrEP
initiation
% (n/N)
Unadjusted ORc
(95% CI)
Adjusted ORc
(95% CI)
PrEP
adherence
% (n/N)
Unadjusted ORc
(95% CI)
Adjusted ORc
(95% CI)
Age
≥25 76% (102) 0.69 (0.34, 1.39) 76% (69) 4.03 (1.96, 8.28)d 2.95 (1.37, 6.37)e
<25 84% (76) Ref 49% (34) Ref
Highest education
level attained
HS or less 77% (43) Ref 47% (18) Ref
Some college or
vocational school
77% (72) 1.23 (0.51, 2.96) 56% (35) 1.33 (0.57, 3.11)
Two-year college or greater 82% (63) 0.86 (0.38, 1.96) 83% (50) 6.80 (2.54, 18.2)d
Employment status
Unemployed, disabled or other 66% (40) Ref 56% (19) Ref
Part time or self-employed 84% (67) 2.30 (1.02, 5.20)e 2.11 (0.84, 5.28) 56% (35) 0.90 (0.38, 2.16)
Full time 84% (71) 2.47 (1.10, 5.59)e 1.48 (0.54, 4.03) 75% (49) 2.62 (1.04, 6.61)e
Annual income
<$20K 74% (80) Ref 54% (38) Ref
$20K to $40K 85% (47) 1.87 (0.77, 4.57) 68% (30) 2.17 (0.92, 5.09)
≥$40K 80% (48) 1.38 (0.57, 3.31) 73% (32) 4.40 (1.66, 11.6)e
Have enough money,
past six months
Yes 85% (114) 2.12 (1.08, 4.16)e 1.81(0.79, 4.14) 74% (78) 3.59 (1.78, 7.24)d 3.58 (1.66, 7.74)e
No 70% (64) Ref 45% (25) Ref
Health insurance
Yes 77% (120) 0.74 (0.35, 1.55) 66% (71) 1.38 (0.68, 2.81)
No 82% (58) Ref 60% (32) Ref
Gay identity
Yes 81% (135) 1.94 (0.95, 3.96) 66% (83) 1.94 (0.88, 4.31)
No 72% (43) Ref 56% (20) Ref
Ever incarcerated
Yes 74% (51) 0.93 (0.46, 1.90) 56% (25) 0.68 (0.32, 1.43)
No 81% (124) Ref 68% (77) Ref
Any alcohol use, past
three months
Yes 79% (158) 1.28 (0.48, 3.39) 62% (88) 0.28 (0.08, 1.05)
No 71% (17) Ref 82% (14) Ref
Any marijuana use,
past three months
Yes 79% (87) 1.30 (0.67, 2.53) 57% (45) 0.59 (0.30, 1.16)
No 78% (88) Ref 71% (57) Ref
Any other drug use,
past three months
Yes 84% (70) 2.16 (1.04, 4.49)e 2.30 (0.99, 5.34) 50% (9) 0.51 (0.18, 1.43)
No 76% (108) Ref 66% (94) Ref
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Table 2. (Continued)
PrEP initiation (N = 178a) PrEP adherence (N = 161a,b)
PrEP
initiation
% (n/N)
Unadjusted ORc
(95% CI)
Adjusted ORc
(95% CI)
PrEP
adherence
% (n/N)
Unadjusted ORc
(95% CI)
Adjusted ORc
(95% CI)
Poly drug use, past
three months
Yes 84% (26) 1.95 (0.68, 5.59) 38% (3) 0.28 (0.06, 1.27)
No 78% (152) Ref 65% (100) Ref
Depressive symptoms
Yes 82% (54) 1.40 (0.66, 2.96) 51% (24) 0.44 (0.21, 0.89)
No 77% (123) Ref 69% (79) Ref
Any STI
Yes 54% (14) 0.59 (0.25, 1.41)
No 66% (89) Ref
Number of male partners, past
three months median (IQR)
3 (1,5) 1.06 (0.98, 1.14) 3 (1,5) 0.99 (0.96, 1.03)
Any primary male partners,
past three months
Yes 78% (58) 1.10 (0.54, 2.23) 62% (32) 0.92 (0.45, 1.86)
No 79% (117) Ref 65% (70) Ref
Any casual male sex
partners, past three months
Yes 83% (133) 2.11 (1.05, 4.27)e 65% (78) 1.07 (0.50, 2.32)
No 69% (42) Ref 62% (24) Ref
Condomless anal sex with HIV
positive or unknown
primary male partner
Yes 88% (21) 2.05 (0.57, 2.28) 74% (14) 1.93 (0.65, 5.78)
No 78% (156) Ref 61% (89) Ref
Condomless anal sex with
HIV positive or unknown
casual male partner
Yes 91% (72) 4.40 (1.66, 11.7)e 4.43 (1.68, 11.68)e 68% (45) 1.49 (0.68, 3.25)
No 72% (105) Ref 61% (58) Ref
Any female sex partners,
past three months
None 80% (157) Ref 66% (96) Ref
At least one 70% (19) 0.55 (0.22, 1.41) 43% (6) 0.34 (0.11, 1.07)
Knowledge of partner
taking PrEP before sex
Yes 86% (104) 2.89 (1.46, 5.74)e 1.68 (0.72, 3.90). 69% (68) 2.15 (1.07, 4.31)e 2.22 (1.03,4.79)e
No 70% (71) Ref 56% (34) Ref
Knowledge of PrEP to
prevent HIV infection
Yes 86% (105) 3.69 (1.81, 7.50)f 2.14 (0.89, 5.17) 69% (68) 2.48 (1.19, 5.18)e
No 69% (70) Ref 56% (34) Ref
Number of C4 sessions
(median, IQR)
NA NA 5 (2, 6) 0.87 (0.72, 1.04)
aRow percentages are based on non-missing data. bIncludes participants who had initiated PrEP by week 26. cAll models were adjusted for study
site. dp < 0.001. ep < 0.05. fC4 is a continuous variable in the regression model.
Wheeler DP et al. Journal of the International AIDS Society 2019, 22:e25223
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25223/full | https://doi.org/10.1002/jia2.25223
8
HIV-infected or status unknown casual partner was signifi-
cantly associated with PrEP initiation, suggesting that BMSM
are able to identify their own potential risk and are willing to
take steps to protect themselves. This opens the possibility
that if providers are educated to work with BMSM and to ask
questions in culturally and contextually relevant ways, they
could assist men in making decisions and developing action
steps to reduce likelihood of HIV acquisition and/or transmis-
sion. Programmes and policies could adopt such practices and
institutionalize these for public health impacts.
In considering this outcome, findings from this and other
studies [41] suggest that BMSM have many situational (e.g.
income insufficiency) and structural barriers (e.g. incarceration
and racial discriminatory experiences), that both hinder access
to and discourage utilization of services. These situational and
contextual factors must be incorporated into biomedical and
behavioural intervention services in order to be impactful for
this group. Without these important activities, biomedical
interventions alone are not likely to achieve their optimal
goals as these situational and contextual factors have very real
and powerful impacts on the lives of many BMSM [66–68].
Beyond behavioural interventions, HPTN 073 findings pro-
vide important content for programme and policy develop-
ment. Care coordination models have been shown to be
successful for promoting care engagement, retention and
treatment adherence among people living with HIV by help-
ing them to address social and structural impediments that
interfere with attaining health goals [69–74]. There remains
a significant gap in research investigating whether care
coordination approaches can produce similar gains in PrEP
programme retention and PrEP adherence.
4.1 | Limitations
The findings from this study should be interpreted in the light
of several limitations: lack of a randomized control design, the
small sample size; use of self-reported sexual and drug use
behaviour period of recall; and social desirability. Longer term
trials, which have incidence as an endpoint are needed for
BMSM in the United States.
Generalizability of findings is limited as sites reflect three
regions of the US (Los Angeles, North Carolina and Washing-
ton, D.C.) using convenience sampling.
Finally, the assessment of community continuation of PrEP
was outside the scope of this study.
5 | CONCLUSIONS
Findings from the HPTN 073 study contribute to advancing
knowledge about uptake and adherence with PrEP among
BMSM. To engage BMSM in PrEP, programmes need to commit
to assist men with navigating the social complexities in which
they exist. Our findings suggest that the C4 intervention may
be a useful adjunct to PrEP allowing this disproportionately
affected population to garner the benefits of the latter interven-
tion for HIV prevention.
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